| 영문 | microbiology | 한글 | 미생물학 |
|---|---|---|---|
| 설명 | 미생물(microorganism)을 연구대상으로 하는 학문. 미생물이라는 생명체를 대상으로 연구하는 생명과학의 한 분야이다. 분류-생리-유전에 관한 것은 생물화학-생물물리학-면역학-유전학 분야에서 주로 연구하고 생태학적 분야를 비롯한 응용분야는 유전자공학-발효공학에서 다룬다. 초기의 미생물학은 사람-동물-곡식류의 병원미생물을 주로 다루는 의학-수의학-식물병리학에서 시작하여, 식품의 발효와 저장문제를 다루는 식품과학과 함께 발전해 왔다. 그러나 오늘날에는 생명현상을 밝히는 기초학문으로서 분자생물학과 함께 중요한 위치를 차지하며, 유전공학과 항생물질의 생산 또는 에너지와 환경오염의 문제 해결에도 중요한 역할을 하고 있다. |
||
| CUMITECH | Cumulative Techniques and Procedures in Clinical Microbiology |
|---|---|
| CR | calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio... |
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| AAM | acute aseptic meningitis; American Academy of Microbiology; amino acid mixture; African American Mal... |
| ASM | acid sphingomyelinase; airway smooth muscle; American Society for Microbiology; anterior scalenus mu... |
| ACTG | AIDS Clinical Trials Group |
|---|---|
| ASCO | American Society of Clinical Oncology |
| CAI | Clinical Activity Index |
| CAL | Clinical Attachment Level |
| CCR | Clinical Complete Response |
| air microbiology | The presence of bacteria, viruses, and fungi in the air. This term is not restricted to pathogenic organisms. (12 Dec 1998) |
|---|---|
| cellular microbiology | <study> A new discipline emerging at the interface between cell biology and microbiology. One major focus of this new field is on the interference of pathogenic bacteria with many eukaryotic cell functions, such as maturation of intracellular compartments, internal cellular communication, or even cell division and differentiation. The study of cellular mcirobiology in this respect, is providing a sophisticaled tool kit for mammalian cell biologists. (26 Mar 1998) |
| microbiology | <study> The study of organisms that are too small to be seen with the naked eye, such as bacteria, viruses and yeasts. (09 Oct 1997) |
| water microbiology | The presence of bacteria, viruses, and fungi in water. This term is not restricted to pathogenic organisms. (12 Dec 1998) |
| soil microbiology | The presence of bacteria, viruses, and fungi in the soil. This term is not restricted to pathogenic organisms. (12 Dec 1998) |
| industrial microbiology | The study, utilization, and manipulation of those microorganisms capable of economically producing desirable substances or changes in substances, and the control of undesirable microorganisms. (12 Dec 1998) |
| environmental microbiology | The study of microorganisms living in a variety of environments (air, soil, water, etc.) and their pathogenic relationship to other organisms including man. (12 Dec 1998) |
| food microbiology | The presence of bacteria, viruses, and fungi in food and food products. This term is not restricted to pathogenic organisms: the presence of various non-pathogenic bacteria and fungi in cheeses and wines, for example, is included in this concept. (12 Dec 1998) |
| Addison's clinical planes | A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison. (05 Mar 2000) |
| pathology, clinical | A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids. (12 Dec 1998) |
| chemistry, clinical | The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy. (12 Dec 1998) |
| pharmacology, clinical | The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. (12 Dec 1998) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|